{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:40:14Z","timestamp":1791412814835,"version":"4.3.3"},"reference-count":153,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"19","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Acquired resistance (AR) to immune checkpoint inhibitors (ICIs) remains a major obstacle to durable clinical benefit in non\u2013small cell lung cancer (NSCLC). Emerging after initial responses, AR reflects tumor evolution, immune escape, and metabolic reprogramming. Key mechanisms may include impaired antigen presentation (\u03b22-microglobulin, human leukocyte antigen mutations), T-cell exhaustion, and remodeling of the tumor microenvironment (TME). In this review, we summarize the current understanding of ICIs resistance and highlight therapeutic strategies under investigation to overcome it. Novel approaches include next-generation ICIs targeting TIGIT and LAG-3, epigenetic modulators (HDAC, DNMT inhibitors), and metabolic agents relevant to\n                      <jats:italic toggle=\"yes\">STK11<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">KEAP1<\/jats:italic>\n                      mutations. Additional strategies aim to reprogram the TME through AXL or multikinase inhibition, tumor-treating fields, and cytokine- and\/or gene-based therapies. Cellular immunotherapies (tumor-infiltrating lymphocytes, T-cell receptors, chimeric antigen receptor-T), antibody-drug conjugates, and vaccines offer complementary means to restore antitumor immunity. Advancing the field will require biomarker-driven patient selection and rational combinations to overcome AR and achieve more durable, personalized immunotherapy outcomes in NSCLC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-03026","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T19:59:10Z","timestamp":1779479950000},"page":"1833-1844","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Overcoming Primary and Acquired Resistance to Immunotherapy in Non\u2013Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7046-0059","authenticated-orcid":false,"given":"Cassio Murilo","family":"Hidalgo-Filho","sequence":"first","affiliation":[{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"Department of Oncology, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil"},{"name":"Oncologia Clinica, Instituto do Cancer do Estado de Sao Paulo ICESP, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7587-9445","authenticated-orcid":false,"given":"Valentina","family":"Santo","sequence":"additional","affiliation":[{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1665-3367","authenticated-orcid":false,"given":"Eleonora","family":"Gariazzo","sequence":"additional","affiliation":[{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-051X","authenticated-orcid":false,"given":"Mihaela","family":"Aldea","sequence":"additional","affiliation":[{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pecci","sequence":"additional","affiliation":[{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-064X","authenticated-orcid":false,"given":"Fran\u00e7ois-Xavier","family":"Danlos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8765-3044","authenticated-orcid":false,"given":"Gilberto","family":"de Castro Junior","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil"},{"name":"Oncologia Clinica, Instituto do Cancer do Estado de Sao Paulo ICESP, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-2678","authenticated-orcid":false,"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02885"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01977-y"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00975"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005921"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.10.013"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.007"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.1981"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01235-4"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001620"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01748"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.2151"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1638"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00228-2"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae006"},{"key":"e_1_3_6_25_2","first-page":"100675","article-title":"Three-year overall survival outcomes and correlative analyses in patients with non-small-cell lung cancer and high (50-89%) versus very high (\u226590%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab","volume":"5","author":"Ricciuti B","year":"2024","unstructured":"Ricciuti B, Elkrief A, Lin J, et al: Three-year overall survival outcomes and correlative analyses in patients with non-small-cell lung cancer and high (50-89%) versus very high (\u226590%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab. JTO Clin Res Rep 5:100675, 2024","journal-title":"JTO Clin Res Rep"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.017"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36328-z"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.09.010"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0689"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.03.011"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.011"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.01.091"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100431"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.1381"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07943-7"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00429-2"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8655"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00732-4"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1825"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.024"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0834-6"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3023"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109071"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0575"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99524-1"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01042"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0237"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102065"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.05.019"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3101"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0532"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02747"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.12.018"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002891"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100187"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.008"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0639-4"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.12.013"},{"key":"e_1_3_6_62_2","first-page":"00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer","volume":"23","author":"Ricciuti B","year":"2024","unstructured":"Ricciuti B, Lamberti G, Puchala SR, et al: Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer. J Clin Oncol 23:00580, 2024","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0593"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5"},{"key":"e_1_3_6_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102329"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01738-6"},{"key":"e_1_3_6_69_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0828"},{"key":"e_1_3_6_70_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1575"},{"key":"e_1_3_6_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.04.003"},{"key":"e_1_3_6_72_2","first-page":"6","article-title":"Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy","volume":"43","author":"Ndembe G","year":"2024","unstructured":"Ndembe G, Intini I, Moro M, et al: Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. J Exp Clin Cancer Res CR 43:6, 2024","journal-title":"J Exp Clin Cancer Res CR"},{"key":"e_1_3_6_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.01.012"},{"key":"e_1_3_6_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.02.006"},{"key":"e_1_3_6_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00339-6"},{"key":"e_1_3_6_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.07.019"},{"key":"e_1_3_6_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-019-0224-x"},{"key":"e_1_3_6_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35948-9"},{"key":"e_1_3_6_79_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01499-1"},{"key":"e_1_3_6_80_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0725"},{"key":"e_1_3_6_81_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300271"},{"key":"e_1_3_6_82_2","first-page":"01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","volume":"24","author":"Tawbi HA","year":"2024","unstructured":"Tawbi HA, Hodi FS, Lipson EJ, et al: Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047. J Clin Oncol 24:01124, 2024","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_83_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003776"},{"key":"e_1_3_6_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2295"},{"key":"e_1_3_6_85_2","first-page":"A678","article-title":"596 AMBER, Part 2B: A phase 1 study of cobolimab plus dostarlimab in patients with advanced\/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy","volume":"11","author":"Davar D","year":"2023","unstructured":"Davar D, Eroglu Z, Milhem M, et al: 596 AMBER, Part 2B: A phase 1 study of cobolimab plus dostarlimab in patients with advanced\/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy. J Immunother Cancer 11:A678, 2023","journal-title":"J Immunother Cancer"},{"key":"e_1_3_6_86_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-079132"},{"key":"e_1_3_6_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00226-1"},{"key":"e_1_3_6_88_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2343272"},{"key":"e_1_3_6_89_2","unstructured":"Merck provides update on KeyVibe and KEYFORM clinical development programs evaluating investigational vibostolimab and favezelimab fixed-dose combinations with pembrolizumab\u2014Merck.com. https:\/\/www.merck.com\/news\/merck-provides-update-on-keyvibe-and-keyform-clinical-development-programs-evaluating-investigational-vibostolimab-and-favezelimab-fixed-dose-combinations-with-pembrolizumab\/"},{"key":"e_1_3_6_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01655-5"},{"key":"e_1_3_6_91_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5312"},{"key":"e_1_3_6_92_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231204854"},{"key":"e_1_3_6_93_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31764-9"},{"key":"e_1_3_6_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01332-8"},{"key":"e_1_3_6_95_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.700407"},{"key":"e_1_3_6_96_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT051"},{"key":"e_1_3_6_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100593"},{"key":"e_1_3_6_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.012"},{"key":"e_1_3_6_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.10.014"},{"key":"e_1_3_6_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01848-3"},{"key":"e_1_3_6_101_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011377"},{"key":"e_1_3_6_102_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004322"},{"key":"e_1_3_6_103_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8670"},{"key":"e_1_3_6_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2477"},{"key":"e_1_3_6_105_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8652"},{"key":"e_1_3_6_106_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00912"},{"key":"e_1_3_6_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.004"},{"key":"e_1_3_6_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100537"},{"key":"e_1_3_6_109_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02166"},{"key":"e_1_3_6_110_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8671"},{"key":"e_1_3_6_111_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01460-1"},{"key":"e_1_3_6_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.04.015"},{"key":"e_1_3_6_113_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01154-x"},{"key":"e_1_3_6_114_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2091-y"},{"key":"e_1_3_6_115_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07156-w"},{"key":"e_1_3_6_116_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86007-w"},{"key":"e_1_3_6_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113714"},{"key":"e_1_3_6_118_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3305"},{"key":"e_1_3_6_119_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9125"},{"key":"e_1_3_6_120_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9161"},{"key":"e_1_3_6_121_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02808-y"},{"key":"e_1_3_6_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.11.009"},{"key":"e_1_3_6_123_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-3916"},{"key":"e_1_3_6_124_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-23-A115"},{"key":"e_1_3_6_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.002"},{"key":"e_1_3_6_126_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01544"},{"key":"e_1_3_6_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.050"},{"key":"e_1_3_6_128_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00733"},{"key":"e_1_3_6_129_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2631"},{"key":"e_1_3_6_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.582"},{"key":"e_1_3_6_131_2","article-title":"SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR\/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study","volume":"41","author":"Zhao Y","year":"2023","unstructured":"Zhao Y, Zhang L, Fang W, et al: SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR\/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study. J Clin Oncol 41, 2023 (suppl 16; abstr 9025)","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_132_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3010"},{"key":"e_1_3_6_133_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2"},{"key":"e_1_3_6_134_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7"},{"key":"e_1_3_6_135_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233"},{"key":"e_1_3_6_136_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1334"},{"key":"e_1_3_6_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.225"},{"key":"e_1_3_6_138_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y"},{"key":"e_1_3_6_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1009"},{"key":"e_1_3_6_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.10.016"},{"key":"e_1_3_6_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114224"},{"key":"e_1_3_6_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00319-2"},{"key":"e_1_3_6_143_2","volume-title":"FDA Grants Accelerated Approval to Afamitresgene Autoleucel for Unresectable or Metastatic Synovial Sarcoma","author":"FDA","year":"2024","unstructured":"FDA: FDA Grants Accelerated Approval to Afamitresgene Autoleucel for Unresectable or Metastatic Synovial Sarcoma. Silver Spring, MD, FDA, 2024"},{"key":"e_1_3_6_144_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8650","article-title":"AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8\u03b1\/\u03b2 coreceptor, and a FAS41BB switch receptor in patients with advanced\/metastatic solid tumors","volume":"42","author":"Mitchell S","year":"2024","unstructured":"Mitchell S, Khan B, Payumo F, et al: AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8\u03b1\/\u03b2 coreceptor, and a FAS41BB switch receptor in patients with advanced\/metastatic solid tumors. J Clin Oncol 42, 2024 (suppl 16; abstr TPS8650)","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_145_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008668"},{"key":"e_1_3_6_146_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03479-y"},{"key":"e_1_3_6_147_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03315-3"},{"key":"e_1_3_6_148_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0"},{"key":"e_1_3_6_149_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01674-3"},{"key":"e_1_3_6_150_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-011-1003-3"},{"key":"e_1_3_6_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.035"},{"key":"e_1_3_6_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.006"},{"key":"e_1_3_6_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1452"},{"key":"e_1_3_6_154_2","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096360059250131075456"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-03026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:00:23Z","timestamp":1782511223000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-03026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":153,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["10.1200\/JCO-25-03026"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-03026","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}